Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR33532823

— · C

7c09d96b-04a4-5cfa-b8ee-bffda7eb8c5a

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
  • IL6_JAK_STAT3_SIGNALING+0.530
  • TNFA_SIGNALING_VIA_NFKB+0.530
  • ANGIOGENESIS+0.520
  • INFLAMMATORY_RESPONSE+0.520
  • COAGULATION+0.460
  • ALLOGRAFT_REJECTION+0.430
  • COMPLEMENT+0.430
  • KRAS_SIGNALING_UP+0.410
  • PANCREAS_BETA_CELLS+0.370

Top 10 suppressed

  • E2F_TARGETS-0.360
  • MITOTIC_SPINDLE-0.360
  • G2M_CHECKPOINT-0.280
  • MYC_TARGETS_V2-0.240
  • DNA_REPAIR-0.150
  • PI3K_AKT_MTOR_SIGNALING-0.100
  • NOTCH_SIGNALING-0.090
  • WNT_BETA_CATENIN_SIGNALING-0.040
  • GLYCOLYSIS-0.030
  • BILE_ACID_METABOLISM-0.020

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1MNG553
mng-umap@100
——0.933
2MDT-AP-2651
medullo-epn-umap@date-based
MedMedulloblastoma0.916
327871087-0449-4f04-bc72-a975681a198a
colon-landscapes@1
——0.901
4sclcM1201764A_S68.txt
lung-landscapes@6
—cohortMD20.900
5R316
bladder-landscape@3
——0.897
6SRR820256
brain-umap@2
GTEX—0.891
7SRR663693
brain-umap@2
GTEX—0.890
8SRR1323196
brain-umap@2
GTEX—0.890
9MDT-AP-0410
medullo-epn-umap@date-based
MedMedulloblastoma0.884
10cc158c27-a2f0-4403-ae01-913bfcc623cc
colon-landscapes@1
——0.884

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 37 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.560Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.530Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.530Inavolisib— uncovered
ANGIOGENESIS0.520Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.520Idelalisib— uncovered
COAGULATION0.460Binimetinib— uncovered
ALLOGRAFT_REJECTION0.430Idelalisib— uncovered
COMPLEMENT0.430Inavolisib— uncovered
KRAS_SIGNALING_UP0.410Inavolisib— uncovered
PANCREAS_BETA_CELLS0.370Cobimetinib— uncovered
ESTROGEN_RESPONSE_LATE0.360Idelalisib— uncovered
IL2_STAT5_SIGNALING0.360Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.350Inavolisib— uncovered
HYPOXIA0.330Idelalisib— uncovered
MYOGENESIS0.330Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.330Inavolisib— uncovered
ANDROGEN_RESPONSE0.320Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.320Remibrutinib— uncovered
APICAL_SURFACE0.300Temsirolimus— uncovered
KRAS_SIGNALING_DN0.300Remibrutinib— uncovered